Associations of multiple lipoprotein and apolipoprotein measures with worsening of glycemia and incident type 2 diabetes in 6607 non-diabetic Finnish men
Introduction
Type 2 diabetes is associated with atherogenic dyslipidemia, including elevated levels of plasma triglycerides (TG), very-low density lipoprotein (VLDL) particles, post-prandial triglyceride-rich lipoprotein remnants and apoliporotein B (apoB), and low levels of high density lipoprotein cholesterol (HDL-C) [1], [2]. These atherogenic changes precede type 2 diabetes by several years and are associated with high risk of cardiovascular events in type 2 diabetes [3], [4], [5], [6].
The compositional changes of lipoprotein particles occur in type 2 diabetes, including the formation of atherogenic small dense LDL (sd-LDL) and small HDL (s-HDL) particles, and the predominance of large VLDL particles. In prospective studies, increased levels of triglycerides [7], sd-LDL [8], large VLDL particles (l-VLDL), and s-HDL [8], [9], [10], have been shown to be associated with increased risk of diabetes, whereas increased levels of large HDL particles [11], [12] and apoA1 [11] have been shown to be protective of diabetes. Also lipoprotein ratios, which reflect the proportion of atherogenic to antiatherogenic lipoproteins, have been proposed as potential markers for the future risk of type 2 diabetes [13], [14].
Results from previously published studies have been inconsistent with regard to what are the best lipoprotein and apolipoprotein markers predicting the progression to overt type 2 diabetes. One report previously showed that apoB level is a better predictor for the future risk of type 2 diabetes compared with LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) [15]. Another study reported that the apoA1/HDL-C ratio is superior to other lipid variables in predicting the development of type 2 diabetes [16]. However, none of the previous studies has evaluated lipoprotein and apolipoprotein traits and their ratios as predictors for the worsening of glycemia and changes in insulin sensitivity and insulin secretion in non-diabetic participants.
We investigated the various lipoprotein and apolipoprotein traits and their ratios as predictors for the worsening of glycemia and incident type 2 diabetes in a 5.9-year population-based follow-up study. We also investigated the associations of lipoprotein traits, apolipoproteins and ratios with insulin resistance and insulin secretion.
Section snippets
Subjects and clinical measurement at the baseline study
The Metabolic Syndrome in Men (METSIM) Study, comprising 10,197 Finnish men aged from 45 to 70 years and randomly selected from the population register of Kuopio, Eastern Finland (population 95,000), was performed in 2005–2010 at the University of Eastern Finland. The present report includes 6607 non-diabetic participants without statin treatment at baseline (age 56 ± 7 years, body mass index (BMI) 26.6 ± 3.8 kg/m2, mean ± SD). Participants with previously diagnosed type 1 diabetes (N = 25),
Clinical and laboratory characteristics of the study population
We compared selected clinical and laboratory traits between participants who remained non-diabetic and participants who developed type 2 diabetes during the prospective METSIM study (Supplementary Table 1). Compared to participants who did not develop diabetes, participants with incident type 2 diabetes were more obese, older, less physically active, had lower levels of apoA1, HDL-C and large HDL particles, higher levels of apoB, small and large VLDL particles, and the ratios of apoA1/HDL-C,
Conclusions
In a 5.9-year follow-up of our large population-based METSIM study we evaluated the associations of different lipoprotein traits, apolipoproteins and their ratios with the worsening of glycemia, incident type 2 diabetes, and potential mechanisms explaining these associations. Our results suggest that compared to single lipoprotein measurements, lipoprotein and apolipoprotein ratios such as apoA1/HDL-C and apoB/LDL-C are better predictors for the worsening of glycemia and incident type 2
Conflicts of interest
The authors have declared no conflicts of interest.
Acknowledgments
This work has been supported by the grants from the Finnish Diabetes Research Foundation (M.L.), the Academy of Finland (to M.L. and A.S.), the Finnish Cardiovascular Research Foundation (to M.L.), the Strategic Research Funding from the University of Eastern Finland, Kuopio (to M.L.), Finland, EVO Grant 5263 from the Kuopio University Hospital (to M.L.), the Sigrid Juselius Foundation (M.A.-K.), the Novo Nordisk Foundation (M.A.-K.), and the Strategic Research Funding from the University of
References (31)
- et al.
Plasma lipoproteins and incidence of non-insulin-dependent diabetes mellitus in Pima Indians: protective effect of HDL cholesterol in women
Atherosclerosis
(1997) - et al.
Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: population-based cohort study
Clin. Biochem.
(2010) - et al.
The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks
Int. J. Cardiol.
(2010) - et al.
Dyslipidemia in type 2 diabetes
Med. Clin. North Am.
(2004) - et al.
Diabetic dyslipidaemia
Curr. Opin. Lipidol.
(2006) Diabetic dyslipidaemia: from basic research to clinical practice
Diabetologia
(2003)- et al.
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
Arterioscler. Thromb. Vasc. Biol.
(2008) - et al.
Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis
Arteriosclerosis
(1989) Clinical review 124. Diabetic dyslipidemia: causes and consequences
J. Clin. Endocrinol. Metab.
(2001)- et al.
Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study
Circulation
(2005)
Lipoprotein particles and incident type 2 diabetes in the multi- ethinic study of atherosclerosis Advanced online publication
Diabetes Care
Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women
Diabetes
Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women
Circulation
HDL cholesterol subfractions and risk of developing type 2 diabetes among Pima Indians
Diabetes Care
Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study
J. Clin. Endocrinol. Metab.
Cited by (49)
Association between high-density lipoprotein cholesterol to apolipoprotein A ratio and diabetic retinopathy: A cross-sectional study
2023, Journal of Diabetes and its ComplicationsMahalanobis distance, a novel statistical proxy of homeostasis loss is longitudinally associated with risk of type 2 diabetes
2021, EBioMedicineCitation Excerpt :For instance, in a study comprising 11,896 subjects from four well characterized prospective cohorts, 113 out of 229 metabolites were associated with risk of T2D development [12]. Several other observational studies have confirmed these findings [13–15]. Remarkably, the assessment of how the simultaneous variation of such biomarkers among themselves could reflect the loss of homeostasis remains underexplored in the context of T2D development.
Association between lipids and apolipoproteins on type 2 diabetes risk; moderating effects of gender and polymorphisms; the ATTICA study
2020, Nutrition, Metabolism and Cardiovascular DiseasesCitation Excerpt :It might also be a reflection that the Dutch cohort data was only adjusted for glucose and not insulin, so unable to adjust for insulin resistance (HOMA-IR); a known predictive of risk of developing T2DM [34,35]. The pattern which protective effects in males of apoA1/HDLc and increasing risk from apoB/LDLc ratios were consistent with Abbasi et al. [13] and data concerning apoB/LDLc ratio additionally concurs with the male-only cohort reported by Fizelova et al. [36]. However, this is the first cohort to suggest an effect of apoA1/triglycerides as modifying risk of developing T2DM in a long-term prospective cohort.
Biomarkers for type 2 diabetes
2019, Molecular Metabolism